Valuation
- Market cap
- 48,135,000
- Revenue TTM
- $570,000
- Net income TTM
- $-26,480,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -4,645.61%
- Debt to equity
- 0.00
Trading
- Volume
- 99,100
- Avg volume
- 169,020
- Day's range
- $17.99 – $19.86
- Shares out
- 2,670,000
- Stochastic %K
- 75%
- Beta
- 2.10
- Analysts
- Moderate Buy
- Price target
- $59.00
Company profile
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://www.yarrowbioscience.com
- Address
- 40 10 th Avenue, Floor 7, New York, United States
Latest news
No headlines yet.